U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H37N3O7S
Molecular Weight 547.664
Optical Activity ( - )
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DARUNAVIR

SMILES

[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC3=CC=CC=C3)[C@H](O)CN(CC(C)C)S(=O)(=O)C4=CC=C(N)C=C4

InChI

InChIKey=CJBJHOAVZSMMDJ-HEXNFIEUSA-N
InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H37N3O7S
Molecular Weight 547.664
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23708741 | http://adisinsight.springer.com/drugs/800016726

Darunavir (trade name Prezista) is an orally active bis-furan-sulfonamide inhibitor of human immunodeficiency virus (HIV-1) protease. Darunavir was developed by Tibotec Pharmaceuticals (now Janssen R&D Ireland). Darunavir is indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. The drug is co-administered with low-dose ritonavir and other anti-HIV agents. It is the only antiretroviral that has been registered at two different doses, 800/100 mg once-daily or 600/100 mg twice-daily, allowing its administration throughout the entire course of HIV disease, from naive subjects without any HIV-1 resistance to heavily treatment-experienced subjects with widespread triple-class family resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.5 pM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PREZISTA

Approved Use

PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents.

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5272 ng/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
93026 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
124698 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
57055 ng × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
126377 ng × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15 h
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5%
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Ritonavir
DARUNAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Disc. AE: Headache, Gastrointestinal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Headache (grade 3, 0.79%)
Gastrointestinal disorder NOS (5.51%)
Sources: Page: p.227
3200 mg single, oral
Overdose
Dose: 3200 mg
Route: oral
Route: single
Dose: 3200 mg
Sources: Page: p.22
healthy
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Disc. AE: Drug-induced hepatitis, Hepatitis acute...
AEs leading to
discontinuation/dose reduction:
Drug-induced hepatitis
Hepatitis acute
Cytolytic hepatitis
Reaction skin (grade 1-3)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Diabetes mellitus
Hyperglycemia
Fat redistribution
Fat tissue increased
Immune reconstitution syndrome
Sources: Page: p.1
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.8
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 1-2, 0.5%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal disorder NOS 5.51%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Headache grade 3, 0.79%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.227
unhealthy, 43
n = 127
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 43
Sex: M+F
Population Size: 127
Sources: Page: p.227
Cytolytic hepatitis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Diabetes mellitus Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Drug-induced hepatitis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Fat redistribution Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Fat tissue increased Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Hepatitis acute Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Hyperglycemia Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Immune reconstitution syndrome Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Stevens-Johnson syndrome Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Toxic epidermal necrolysis Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Reaction skin grade 1-3
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.1
Rash grade 1-2, 0.5%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Co-administed with::
ritonavir, oral(100 mg; qd)
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources: Page: p.8
PubMed

PubMed

TitleDatePubMed
New HIV treatment.
2006 Sep-Oct
Clinical pharmacokinetics of darunavir.
2007
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
2007
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
2007
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2007
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
2007
Antiretroviral treatment of HIV infection: Swedish recommendations 2007.
2007
Anti-HIV drugs.
2007
AIDS in the Third World: how to stop the HIV infection?
2007
Key reports from the XV International HIV Drug Resistance Workshop 2006.
2007
When and how to use tipranavir and darunavir.
2007 Apr
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
2007 Apr
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
2007 Apr 7
Darunavir: promising initial results.
2007 Apr 7
Darunavir (TMC114): a new HIV-1 protease inhibitor.
2007 Aug
Development of therapeutics for AIDS: structure-based molecular targeting.
2007 Aug
Darunavir: a second-generation protease inhibitor.
2007 Aug 1
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
2007 Dec
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
2007 Dec 15
Darunavir (TMC114) approved by the FDA.
2007 Feb
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
2007 Feb 19
48-week study results show DRV's staying power.
2007 Jan
Anti-HIV agents. Darunavir and some antidepressants.
2007 Jan
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
2007 Jul 11
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
2007 Jul 7
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
2007 Jul 7
No patient left behind--better treatments for resistant HIV infection.
2007 Jul 7
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
2007 Jul-Aug
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
2007 Jun
Prezista gets EU approval.
2007 Mar
Editorial comment: impact of darunavir for salvage therapy.
2007 Mar
Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.
2007 Mar
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
2007 Mar 26
Tibotec and Aspen collaborate on Prezista.
2007 May
HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
2007 May
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
2007 May
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
2007 May
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
2007 May 31
Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients.
2007 May-Jun
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
2007 Oct
Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection.
2007 Oct 1
Predicting HIV care costs using CD4 counts from clinical trials.
2007 Sep
Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen.
2007 Sep
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
2007 Sep 1
Tipranavir: a new option for the treatment of drug-resistant HIV infection.
2007 Sep 15
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
2007 Sep 28
Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
2007 Sep 6
Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
2007 Winter
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
2008 Jan
Quality control of protease inhibitors.
2008 Jun
Patents

Sample Use Guides

Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (two 400 mg tablets) taken with ritonavir 100 mg once daily and with food. Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of PREZISTA and ritonavir is based on body weight and should not exceed the treatmentexperienced adult dose. Do not use once daily dosing in pediatric patients. PREZISTA should be taken with ritonavir twice daily and with food.
Route of Administration: Oral
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL). Darunavir demonstrates antiviral activity in cell culture against a broad panel of HIV-1 group M (A, B, C, D, E, F, G), and group O primary isolates with EC50 values ranging from less than 0.1 to 4.3 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:28:19 GMT 2023
Edited
by admin
on Fri Dec 15 16:28:19 GMT 2023
Record UNII
YO603Y8113
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DARUNAVIR
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
Darunavir [WHO-DD]
Common Name English
(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE
Common Name English
((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER
Common Name English
Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
Systematic Name English
DARUNAVIR [MART.]
Common Name English
(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((2S,3R)-4-((4-AMINO-N-ISOBUTYLPHENYL)SULFONAMIDO)-3-HYDROXY-1-PHENYLBUTAN-2-YL)CARBAMATE
Systematic Name English
TMC114
Code English
(-)-DARUNAVIR
Common Name English
DARUNAVIR [USAN]
Common Name English
DARUNAVIR [ORANGE BOOK]
Common Name English
darunavir [INN]
Common Name English
DRV
Common Name English
DARUNAVIR [MI]
Common Name English
DARUNAVIR [EMA EPAR]
Common Name English
TMC-41629
Code English
DARUNAVIR [HSDB]
Common Name English
TMC-114
Code English
DARUNAVIR [VANDF]
Common Name English
UIC-94017
Code English
TMC 114
Code English
Classification Tree Code System Code
WHO-ATC J05AE10
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
LIVERTOX NBK547994
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
NDF-RT N0000175889
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
WHO-ATC J05AR14
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
NDF-RT N0000000246
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
WHO-VATC QJ05AE10
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
NCI_THESAURUS C783
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
Code System Code Type Description
CAS
206361-99-1
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046779
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
DAILYMED
YO603Y8113
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
NDF-RT
N0000190114
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
LACTMED
Darunavir
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
WIKIPEDIA
DARUNAVIR
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
INN
8305
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
HSDB
7788
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL1323
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
FDA UNII
YO603Y8113
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
USAN
RR-31
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
MERCK INDEX
m4099
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY Merck Index
EVMPD
SUB25394
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
NCI_THESAURUS
C65364
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
DRUG CENTRAL
4143
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
DRUG BANK
DB01264
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
CHEBI
367163
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
SMS_ID
100000089367
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
RXCUI
460132
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY RxNorm
PUBCHEM
213039
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
MESH
C482292
Created by admin on Fri Dec 15 16:28:19 GMT 2023 , Edited by admin on Fri Dec 15 16:28:19 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SOLVATE->ANHYDROUS
METABOLIC ENZYME -> INHIBITOR
Ki
SOLVATE->ANHYDROUS
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
BINDING
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
TRANSPORTER -> INHIBITOR
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC